Clinical Trial Update: Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses [Phase 2]

View source ↗

Summary

A Phase 2 trial of twice-daily deferasirox in transfusion-dependent thalassemia patients inadequately responding to high-dose therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusion-dependent Thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD | Phase 2 | Status: WITHDRAWN